US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
biotech · SARS-CoV-2 Infection · Breast Cancer
Henlius USA
Shanghai Henlius Biotech
Henlius USA drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Milpitas, USA HQ
2010 Founded
45 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Milpitas, USA
- Founded
- 2010
- Employees
- 45
- Programs
- 3
- Drugs
- 4
- Patents
- 0
Henlius USA pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Henlius USA drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Henlius USA in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Henlius USA in public FDA and regional records.